CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis

Company Overview

CNS Pharmaceuticals, Inc., headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development. WP1066 is in preclinical stages with plans to progress to early-phase clinical studies, targeting patients who have limited treatment options due to the highly immunosuppressive nature of central nervous system tumors. Together, these candidates reflect the company’s strategy to address both direct cytotoxic and immune-mediated approaches to brain cancer therapy.

Under the leadership of Chairman and Chief Executive Officer Howard J. Robin, CNS Pharmaceuticals completed its initial public offering on the NASDAQ Capital Market under the symbol CNSP. The company conducts clinical trials across North America and collaborates with academic and research institutions to support its development programs. With a dedicated focus on unmet needs in neuro-oncology, CNS Pharmaceuticals aims to advance its pipeline toward regulatory approvals and ultimately provide new treatment options for patients with life-threatening brain tumors.

Key Stats

• Today's Range: $8.91 to $9.30
• 50-Day Range: $5.09 to $10.57
• 52-Week Range: $4.93 to $221.94
• Volume: 12,187 shs
• Average Volume: 24,619 shs
• Market Capitalization: $5.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Hold

CNS Pharmaceuticals Stock Analysis - MarketRank™

CNS Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

CNS Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

CNS Pharmaceuticals has a consensus price target of $20.00, representing about 118.6% upside from its current price of $9.15.

Amount of Analyst Coverage

CNS Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CNS Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CNS Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CNS Pharmaceuticals has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.29% of the float of CNS Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

CNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CNS Pharmaceuticals has recently decreased by 22.30%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CNS Pharmaceuticals does not currently pay a dividend.

Dividend Growth

CNS Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.29% of the float of CNS Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

CNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CNS Pharmaceuticals has recently decreased by 22.30%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added CNS Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CNS Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.07% of the stock of CNS Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 14.02% of the stock of CNS Pharmaceuticals is held by institutions.

CNSP Stock Analysis - Frequently Asked Questions

How have CNSP shares performed this year?

CNS Pharmaceuticals' stock was trading at $72.24 on January 1st, 2025. Since then, CNSP stock has decreased by 87.3% and is now trading at $9.15.

How were CNS Pharmaceuticals' earnings last quarter?

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) released its quarterly earnings results on Thursday, August, 14th. The company reported ($6.42) EPS for the quarter, beating the consensus estimate of ($9.60) by $3.18.

When did CNS Pharmaceuticals' stock split?

CNS Pharmaceuticals's stock reverse split on Friday, February 21st 2025.The 1-50 reverse split was announced on Wednesday, February 19th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did CNS Pharmaceuticals IPO?

CNS Pharmaceuticals (CNSP) raised $9 million in an initial public offering (IPO) on Friday, November 8th 2019. The company issued 2,100,000 shares at $4.00-$5.00 per share. Benchmark acted as the underwriter for the IPO.

How do I buy shares of CNS Pharmaceuticals?

Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CNS Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CNS Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO) and GE Aerospace (GE).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/20/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CNSP
• CIK: 1729427
• Web: www.cnspharma.com
• Phone: 800-946-9185
• Fax: N/A
• Employees: 5
• Year Founded: 2017

Price Target and Rating

• Average Price Target for CNS Pharmaceuticals: $20.00
• High Price Target: $20.00
• Low Price Target: $20.00
• Potential Upside/Downside: +115.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3,748.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.86 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -183.89%
• Return on Assets: -139.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.22
• Quick Ratio: 10.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $64.50 per share
• Price / Book: 0.14

Miscellaneous

• Outstanding Shares: 570,000
• Free Float: 575,000
• Market Cap: $5.29 million
• Optionable: Not Optionable
• Beta: 2.68